Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of BRAF/MEK-inhibitor therapy for epithelioid glioblastoma with a novel BRAFV600 mutation.

Acta neuropathologica communications - 6 Aug 2024

Steininger J, Buszello C, Oertel R, Meinhardt M, Schmid S, Engellandt K, Herold S, Stasik S, Ebrahimi A, Renner B, Thiede C, Eyüpoglu I Y, Schackert G, Beissert S, Meier F, Radke J, Westphal D, Juratli T A

Abstract excerpt

Epithelioid glioblastoma (eGB), a very aggressive and rare brain tumour, is associated with a dismal median overall survival. Effective therapies for patients with eGB, particularly with leptomeningeal dissemination, are still lacking. Here, we describe a case of a 25-year-old male diagnosed with an intramedullary cervical tumour with subsequent leptomeningeal disease. Histopathology identified a highly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Glioblastoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mitogen-Activated Protein Kinase Kinases

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Source

Open in PubMed Open full text

Identifiers

PMID: 39107839
DOI: 10.1186/s40478-024-01834-8
PMCID: PMC11302837

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of BRAF/MEK-inhibitor therapy for epithelioid glioblastoma with a novel BRAFV600 mutation.PMID 39107839Read ↗

[Clinicopathological features for epithelioid glioblastoma: A newly defined tumor by the 2016 World Health Organization Classification of Tumors of the Central Nervous System].Semantic proximity Read ↗

The Significance of BRAF Mutation in the Epithelioid Glioblastoma Subtype: A Systematic Literature Review and a Case Report with a Unique Intraventricular Topography.Semantic proximity Read ↗

Clinicopathological characteristics and treatment outcomes of epithelioid glioblastoma.Semantic proximity Read ↗

Diagnostic and Therapeutic Updates in Leptomeningeal Disease.Semantic proximity Read ↗

Effect of BRAF/MEK Inhibition on Epithelioid Glioblastoma with BRAFV600E Mutation: a Case Report and Review of the Literature.Semantic proximity Read ↗

Abnormal Schwannoma-like Growth of multiple, multifocal BRAF V600E-positive Glioblastoma in the Interior Acoustic Canal with Leptomeningeal Infiltration: a case report.Semantic proximity Read ↗

[Epithelioid glioblastoma with BRAF V600E mutation: a clinicopathological and molecular study].Semantic proximity Read ↗

Clinical Relevance of BRAF V600E Mutation Status in Brain Tumors with a Focus on a Novel Management Algorithm.Semantic proximity Read ↗

A rare case of BRAF V600E-mutated epithelioid glioblastoma with a sarcomatous component.Semantic proximity Read ↗

Integrating Systemic Therapies into the Multimodality Therapy of Patients with Craniopharyngioma.Semantic proximity Read ↗

Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trial.Semantic proximity Read ↗

Effective Treatment of a BRAF V600E-Mutant Epithelioid Glioblastoma Patient By Vemurafenib: A Case ReportSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.